ReviewFrontiers in bioengineering and biotechnology2026
Innovative advances in microalgal high-value products: unlocking potential from bioprocessing to bioindustrial applications.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microalgae as Future Foods: Unlocking Their Potential and Overcoming Barriers to Market Adoption and Commercialization.Foods (Basel, Switzerland) · 2026Review
- Functional and Bioactive Properties of Fermented Microalgae and Their Biomass for Health Applications.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microalgae are increasingly recognized as industrial biotechnology platforms for the sustainable production of high-value products (HVPs), including carotenoids, polyunsaturated fatty acids (PUFAs), polysaccharides, and phycobiliproteins. Their transition from exploratory biomass resources to precision metabolite-focused biofactories reflects growing industrial and regulatory consolidation. This review adopts a product-oriented perspective that moves beyond biomass productivity to evaluate how biological regulation, cultivation strategies, downstream processing, safety assessment, and regulatory readiness collectively determine industrial feasibility and commercialization potential. Rather than treating these components independently, the analysis frames them as interconnected determinants within a systems-level bioindustrial design framework. Emphasis is placed on stress-responsive biosynthesis, extraction and purification bottlenecks, mixotrophic cultivation, and strain engineering approaches as key enablers for improving productivity, process robustness, and cost performance. Carotenoids and omega-3 PUFAs are identified as the most industrially mature microalgal HVPs, supported by scalable production systems and regulatory acceptance, whereas polysaccharides and phycobiliproteins are highlighted as emerging products with expanding bioindustrial relevance. This comparative positioning underscores that industrial maturity depends not solely on biological potential, but on coordinated optimization across strain design, cultivation stability, downstream compatibility, and compliance pathways. By integrating technological innovation with safety and regulatory considerations, this review provides a coherent framework to support scalable, compliant, and sustainable microalgal biomanufacturing. Overall, the synthesis advances a rational roadmap for translating microalgal HVPs from laboratory optimization to economically viable and regulation-ready industrial deployment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.